Shopping Cart
- Remove All
Your shopping cart is currently empty
BMS 753
BMS 753 is an agonist of isotype-selective retinoic acid receptor α (RARα, Ki= 2 nM).
Catalog No. T22049Cas No. 215307-86-1
Select Batch
Purity:98.4%
Contact us for more batch information
BMS 753
Catalog No. T22049Cas No. 215307-86-1
BMS 753 is an agonist of isotype-selective retinoic acid receptor α (RARα, Ki= 2 nM).
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $58 | In Stock | |
| 10 mg | $97 | In Stock | |
| 25 mg | $223 | In Stock | |
| 50 mg | $358 | In Stock | |
| 100 mg | $497 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $58 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "BMS 753"
Isotretinoin
Cited
13-cis-Retinoic acid
T16114759-48-2
Isotretinoin (13-cis-Retinoic acid) binds to and activates nuclear retinoic acid receptors (RARs), which act as transcription factors that promote cell differentiation and apoptosis. This naturally occurring retinoic acid has potential antineoplastic activity, exhibits immunomodulatory and anti-inflammatory responses, and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.
- $36
Size
QTY
CitedOxybenzone
KAHSCREEN BZ-3, Benzophenone 3, Eusolex 4360, Escalol 567
T0499131-57-7
Oxybenzone is a UV filter commonly used in tanning and skin protection agents. It is a derivative of benzophenone and is used as an endocrine disrupting chemical that penetrates the placental and blood-brain barriers. It impairs autophagy, alters epigenetic status and disrupts vitamin X-like receptor signaling in apoptotic neuronal cells.
- $30
Size
QTY
Tamibarotene Cited
NSC 608000, Am 80, Amnolake
T669494497-51-5
Tamibarotene (Amnolake) is an orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity.
- $39
Size
QTY
CitedBexarotene Cited
Ro 26-4455, Targretin, LGD1069
T6410153559-49-0
Bexarotene (LGD1069) is a retinoid analogue that is used to treat the skin manifestations of cutaneous T cell lymphoma (CTCL).
- $30
Size
QTY
CitedTazarotene
Cited
Tazorac, AGN 190168, Zorac
T6696118292-40-3
Tazarotene (Zorac) is a synthetic, topical retinoid. Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene. In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation.
- $32
Size
QTY
CitedTTNPB
AGN191183, Arotinoid acid, Ro 13-7410,AGN-191183, Ro 13-7410
T128871441-28-6
TTNPB (Ro 13-7410,AGN-191183), a potent RAR agonist, inhibits binding of [3H]tRA of human RARα (IC50: 5.1 nM), β (IC50: 4.5 nM), and γ (IC50: 9.3 nM), respectively.
- $33
Size
QTY
Etodolac
Ultradol, AY-24236, Etodolic acid, Lodine
T100241340-25-4
Etodolac (AY-24236) inhibits the activity of cyclooxygenase I and II, thereby preventing the formation of prostaglandin which is involved in the induction of pain, fever, and inflammation. Etodolac is a pyranocarboxylic acid and non-steroidal anti-inflammatory drug (NSAID) with antipyretic and analgesic activities. It also inhibits platelet aggregation by blocking platelet cyclooxygenase and the subsequent formation of thromboxane A2.
- $34
Size
QTY
MSU-42011
T774992456434-36-7In house
MSU-42011 is an orally active retinoid X receptor-like (RXR) agonist. It potently inhibits the expression of iNOS, low SREBP-induced and activated RXR, and p-ERK at the protein level. MSU-42011 has demonstrated antitumor activity in a [kras]-driven mouse model of lung cancer and is effective for the treatment of preclinical [kras]-driven lung cancer with immunomodulatory activity.
- $41
Size
QTY
Acitretin Cited
Ro 10-1670, Etretin
T133055079-83-9
Acitretin (Ro 10-1670) is a second-generation systemic retinoid used in the treatment of psoriasis.
- $111
Size
QTY
CitedER 50891
T22767187400-85-7In house
ER-50891 is a potent retinoic acid receptor alpha (RARα) antagonist. er-50891 reduces the inhibitory effect of allosteric retinoic acid and restores osteoblast differentiation induced by bone morphogenetic protein 2.
- $197
Size
QTY
K-8012
K8012, K 8012
T242401346513-17-4In house
K-8012 is a modulator of the N-terminally truncated RXRα and improves anticancer activities in an RXRα-dependent manner.
- $117
Size
QTY
KCL-286
T785751952276-71-9In house
KCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI).
- $479
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
| Description | BMS 753 is an agonist of isotype-selective retinoic acid receptor α (RARα, Ki= 2 nM). |
| Targets&IC50 | RARα:2 nM (Ki) |
| In vitro | In WT cells, BMS 753 can reduce RAR β Transcription level of 2 in a dose dependent mode. At RAR γ-/- cells, 100 nM of BMS 753 efficiently induces RAR β 2 Transcription. In contrast, in RAR α-/- In cells, up to 100 nM of BMS 753 can not activate RAR β 2[1]. |
| Molecular Weight | 351.4 |
| Formula | C21H21NO4 |
| Cas No. | 215307-86-1 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45.0 mg/mL (128.1 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy BMS 753 | purchase BMS 753 | BMS 753 cost | order BMS 753 | BMS 753 chemical structure | BMS 753 in vitro | BMS 753 formula | BMS 753 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.